JP2024051157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024051157A5 JP2024051157A5 JP2024031183A JP2024031183A JP2024051157A5 JP 2024051157 A5 JP2024051157 A5 JP 2024051157A5 JP 2024031183 A JP2024031183 A JP 2024031183A JP 2024031183 A JP2024031183 A JP 2024031183A JP 2024051157 A5 JP2024051157 A5 JP 2024051157A5
- Authority
- JP
- Japan
- Prior art keywords
- dpb1
- hla
- cancer
- drb1
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609589P | 2017-12-22 | 2017-12-22 | |
| US62/609,589 | 2017-12-22 | ||
| JP2020535008A JP2021507924A (ja) | 2017-12-22 | 2018-12-21 | 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法 |
| PCT/US2018/067380 WO2019126799A1 (en) | 2017-12-22 | 2018-12-21 | Major histocompatibility complex (mhc) compositions and methods of use thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020535008A Division JP2021507924A (ja) | 2017-12-22 | 2018-12-21 | 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024051157A JP2024051157A (ja) | 2024-04-10 |
| JP2024051157A5 true JP2024051157A5 (https=) | 2024-08-28 |
Family
ID=66993888
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020535008A Pending JP2021507924A (ja) | 2017-12-22 | 2018-12-21 | 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法 |
| JP2024031183A Pending JP2024051157A (ja) | 2017-12-22 | 2024-03-01 | 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020535008A Pending JP2021507924A (ja) | 2017-12-22 | 2018-12-21 | 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20210060126A1 (https=) |
| EP (1) | EP3727467A4 (https=) |
| JP (2) | JP2021507924A (https=) |
| WO (1) | WO2019126799A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018316166A1 (en) | 2017-08-07 | 2020-02-06 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| JP7555822B2 (ja) | 2018-04-19 | 2024-09-25 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | ゲノム編集のための組成物および方法 |
| WO2021063340A1 (zh) * | 2019-09-30 | 2021-04-08 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂与免疫检查点抑制剂、酪氨酸激酶抑制剂联合在制备治疗肿瘤药物中的用途 |
| WO2022192701A1 (en) * | 2021-03-12 | 2022-09-15 | T-Cure Bioscience, Inc. | Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7074904B2 (en) * | 1994-07-29 | 2006-07-11 | Altor Bioscience Corporation | MHC complexes and uses thereof |
| EP0995798A1 (en) * | 1998-10-24 | 2000-04-26 | Novimmune Sa | Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances |
| US20050112141A1 (en) * | 2000-08-30 | 2005-05-26 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| WO2002068614A2 (en) * | 2001-02-26 | 2002-09-06 | Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) | Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas |
| GB0109114D0 (en) * | 2001-04-11 | 2001-05-30 | King S College London | Stimulation of the immune system |
| WO2006081629A1 (en) * | 2005-02-04 | 2006-08-10 | Stem Cell Australia Pty Ltd | Adenoviral vectors comprising a nucleic acid encoding a mhc class i molecule and the use of such vectors in cancer therapy. |
| US8491913B2 (en) * | 2009-03-07 | 2013-07-23 | Oregon Health & Science University | Compositions and methods using recombinant MHC molecules for the treatment of stroke |
| WO2012145384A1 (en) * | 2011-04-20 | 2012-10-26 | University Of Washington Through Its Center For Commercialization | Beta-2 microglobulin-deficient cells |
| US20160186208A1 (en) * | 2013-04-16 | 2016-06-30 | Whitehead Institute For Biomedical Research | Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal |
| CN106459990B (zh) * | 2014-02-07 | 2021-06-01 | 麦克马斯特大学 | 三功能t细胞抗原偶联物及其制备方法和用途 |
| CN108026154B (zh) * | 2015-07-01 | 2022-03-08 | 伊玛提克斯生物技术有限公司 | 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物 |
| EP3402901A1 (en) * | 2016-01-11 | 2018-11-21 | Dixon, Janette | Methods for determining tumour phenotypes |
| EP3419657A4 (en) * | 2016-02-25 | 2019-11-06 | Briacell Therapeutics Corp. | CELLULAR CANCER VACCINES AND METHOD FOR SELECTION THEREOF |
| US20170321285A1 (en) * | 2016-05-03 | 2017-11-09 | The Texas A&M University System | Nlrc5 as a biomarker for cancer patients and a target for cancer therapy |
| EP3452101A2 (en) * | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
-
2018
- 2018-12-21 EP EP18891251.3A patent/EP3727467A4/en active Pending
- 2018-12-21 WO PCT/US2018/067380 patent/WO2019126799A1/en not_active Ceased
- 2018-12-21 JP JP2020535008A patent/JP2021507924A/ja active Pending
-
2020
- 2020-06-11 US US16/899,512 patent/US20210060126A1/en not_active Abandoned
-
2024
- 2024-03-01 JP JP2024031183A patent/JP2024051157A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024051157A5 (https=) | ||
| Güssow et al. | The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit. | |
| Aptsiauri et al. | Role of altered expression of HLA class I molecules in cancer progression | |
| Behl et al. | The major histocompatibility complex in bovines: a review | |
| JP2019507608A5 (https=) | ||
| Toes et al. | An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. | |
| Zilberberg et al. | Strategies for the identification of T cell–recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation | |
| CN112912507A (zh) | 甲病毒新抗原载体和干扰素抑制剂 | |
| LEE et al. | Difference in the meq gene between oncogenic and attenuated strains of Marek’s disease virus serotype 1 | |
| CN112351793A (zh) | 免疫检查点抑制剂共表达载体 | |
| CN114072516A (zh) | 经修饰的腺病毒 | |
| Bateman et al. | Human leukocyte antigens and cancer: is it in our genes? | |
| CN106103738A (zh) | 利用超大规模平行测序仪进行简便的hla基因的dna分型方法和试剂盒 | |
| JP2021507924A5 (https=) | ||
| Donaldson | 8 Immunogenetics in liver disease | |
| Dutta et al. | Persistent HPV16/18 infection in Indian women with the A-allele (rs6457617) of HLA-DQB1 and T-allele (rs16944) of IL-1β− 511 is associated with development of cervical carcinoma | |
| DK2572725T3 (en) | MSI-specific frameshift peptides (FSP) for the prevention and treatment of cancer | |
| González et al. | Mucosal immunization of sheep with a Maedi-Visna virus (MVV) env DNA vaccine protects against early MVV productive infection | |
| WO2020072371A1 (en) | Melanoma canine vaccine compositions and methods of use thereof | |
| Bukur et al. | Identification of E2F1 as an important transcription factor for the regulation of tapasin expression | |
| Miyazawa et al. | Influence of MHC genes on spontaneous recovery from Friend retrovirus-induced leukemia | |
| JP2022531976A (ja) | 弱毒化黄熱ウイルス及びがんの処置のためのその使用 | |
| Yoshimoto et al. | A Vβ. 2‐specific superantigen from exogenous mouse mammary tumor virus carried by FM mice | |
| Chiang et al. | Nuclear regulation of HLA class I genes in human trophoblasts | |
| Browning et al. | The HLA‐A, B, C genotype of the class I negative cell line Daudi reveals novel HLA‐A and‐B alleles |